{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"258"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"304"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13","value":"300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40","value":"279"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57","value":"252"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nRamucirumab DP: Ramucirumab (DP): 10 mg/kg IV on day 1 of each 21-day cycle","id":"OG000","title":"Docetaxel + Ramucirumab DP"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug and had evaluable PK data for Ramucirumab and there was no PK data for Docetaxel arm.","reportingStatus":"POSTED","timeFrame":"Cycle 1:Predose,1 hour(hr) post End of Infusion (EOI),48hr,72hr,168hr,336hr post-EOI;Cycle2:Predose,1hr post-EOI; Cycle3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI; Cycle4:Predose,1hr post-EOI;Cycle6 and every other cycle thereafter:Predose,1hr Post EOI","title":"Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab","type":"SECONDARY","unitOfMeasure":"microgram/milliliter (ug/mL)"}